LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Beam Therapeutics Inc. Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease CI
Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates MT
Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing MT
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing MT
Beam Therapeutics Says BEAM-302 Drug Candidate Gets UK Clearance for Alpha-1 Antitrypsin Deficiency MT
Beam Therapeutics Inc. Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency CI
Transcript : Beam Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:35 PM
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating MT
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk MT
Health Care Down as Viking Move Rattles Novo Shares -- Health Care Roundup DJ
Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating MT
Beam Therapeutics Shares Jump on Surprise Q4 Profit MT
Beam Therapeutics Reports Surprise Q4 Profit; Shares Jump in Early Trading MT
Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto MT
North American Morning Briefing : Microsoft Kicks -2- DJ
Beam Therapeutics Shares Gain Following JPMorgan's Upgrade to Overweight MT
JPMorgan Upgrades Beam Therapeutics to Overweight From Neutral, Raises Price Target to $40 From $38 MT
Transcript : Beam Therapeutics Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 11:15 AM
Beam Therapeutics Inc. Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones CI
North American Morning Briefing : Stock Futures -2- DJ
BofA Securities Downgrades Beam Therapeutics to Neutral From Buy, Price Target is $35 MT
Beam Therapeutics Inc. Appoints Christi Shaw to Its Board of Directors CI
North American Morning Briefing : Investors Await -2- DJ
Chart Beam Therapeutics Inc.
More charts
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
23.17 USD
Average target price
48.38 USD
Spread / Average Target
+108.82%
Consensus
  1. Stock Market
  2. Equities
  3. BEAM Stock
  4. News Beam Therapeutics Inc.
  5. Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing